Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.

International journal of oncology

Volumn 16, Issue 3, 2000, Pages 445-454

  Xu, L ^a   Yoneda, J ^a   Herrera, C ^a   Wood, J ^a   Killion, J J ^a   Fidler, I J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; GROWTH FACTOR RECEPTOR; PHTHALAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; VASCULOTROPIN RECEPTOR; VATALANIB;

ANIMAL; ARTICLE; ASCITES; CAPILLARY PERMEABILITY; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; ORAL DRUG ADMINISTRATION; OVARY TUMOR; PATHOLOGY; VASCULARIZATION;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ASCITES; CAPILLARY PERMEABILITY; FEMALE; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PHTHALAZINES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

MLCS; MLOWN;

EID: 0034145605     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.16.3.445     Document Type: Article

References (0)